Raymond James analyst Danielle Brill resumed coverage of Argenx with a Strong Buy rating and $605 price target Argenx successfully secured approval of chronic inflammatory demyelinating polyneuropathy with a broad, clean label at the end of June, and the firm remains bullish that the launch will both exceed investor expectations and will beat consensus estimates, the analyst says. Vyvgartb’s momentum in the generalized myasthenia gravis market remains strong, and should accelerate further with approval of the prefilled syringe by next April, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
Questions or Comments about the article? Write to editor@tipranks.com